🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Shari Damast

Yale Cancer Center

ORCID: 0000-0001-9030-0872

Also affiliated with Yale University, Smilow Cancer Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability”.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025

N/A

2.4DataRank · unranked

80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013

N/A

1.9DataRank · unranked

50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.07.016

N/A

0DataRank · unranked

86 citations

Omar Najjar, Shari Damast, Adriana Blakaj, Joan Tymon‐Rosario, Maryam Shahi +10 more